INCYTE CORPORATION
Services-Commercial Physical & Biological Research- 売上
- $5.1bn
- 時価総額
- $23.8bn
株価 $122.99 · 100株 1万円
| 期 | 23/12 | 24/12 | 25/12 |
|---|---|---|---|
| 売上 | $3.7bn | $4.2bn | $5.1bn |
| 成長率 | — | 14.8% | 21.2% |
| 総利益 | $3.4bn | $3.9bn | $4.8bn |
| 総利益率 | 93.1% | 92.6% | 92.8% |
| 販管費 | $1.2bn | $1.2bn | $1.4bn |
| 販管費率 | 31.3% | 29.3% | 26.8% |
| 営利 | $621m | $61m | $1.5bn |
| 営利率 | 16.8% | 1.4% | 29.5% |
| 純利益 | $598m | $33m | $1.3bn |
| PBR | 4.6 | 6.9 | 4.6 |
| PSR | 6.4 | 5.6 | 4.6 |
| PGPR | 6.9 | 6.1 | 5.0 |
| PER | 40 | 730 | 18 |
| ネットキャッシュ | ▲$16.6bn | ▲$18.1bn | ▲$16.7bn |
| EV/EBITDA | 57.5 | 278.4 | 25.2 |
| Rule of 40 | — | 16% | 51% |
| セールス効率 | — | 565% | 627% |
※Rule of 40は売上成長率+営業利益率、セールス効率は売上総利益増加÷販管費増加(販管費増のときのみ)
